Time to SOUN the alarm this Friday!
41% interest the storm is on the horizon the thing we need is a catalyst. Options expire on Friday with just a little nudge up to $7.50 this would let so many calls be in the market. Regardless of news …
Source material behind every call on the tape.
41% interest the storm is on the horizon the thing we need is a catalyst. Options expire on Friday with just a little nudge up to $7.50 this would let so many calls be in the market. Regardless of news …
I know this is probably an unpopular take, but I think the market is massively overestimating Anthropic’s moat. Bloomberg is reporting that DeepSeek is already preparing for an IPO after reportedly raising at around a $71B valuation, and they got …
Before the loss my total yolo was \~$10k. Mods, if you need me to post all 11 positions individually in the comments just let me know. This is both a YOLO and discussion post. While I’m not going to lay …
I’m traditionally a long term investor, but I’m getting into swing trading to pursue more aggressive account growth. I primarily use ThinkorSwim for trading insights, but just curious what other folks are using? I’m interested in tools for: \- research …
[removed]
I noticed that the same PAX/USDT pair currently appears across three Uniswap V3 pools with very different displayed prices. One pool shows around $0.34, another around $0.92, and a very small pool shows around $0.968. My understanding is that each …
AnaptysBio (ANAB) isn’t your traditional biotech play. Essentially, it is a low-overhead royalty-management company formed around 2 drugs: Jemperli (partnered with GSK) and imsidolimab (partnered with Vanda Pharma). Here’s the relevant backstory. In 2014, ANAB signed a collaboration and exclusive …